Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Aardvark Therapeutics, Inc. ( (AARD) ) has issued an announcement.
On November 4, 2025, Aardvark Therapeutics presented research at the ObesityWeek 2025 conference, showcasing two posters on their metabolic obesity pipeline programs. The presentations highlighted the potential of their TAS2R agonist ARD-101 in reducing weight gain in mice and hunger in adults with obesity, as well as the combination of ARD-101 with other treatments to enhance weight loss and maintenance. These findings could strengthen Aardvark’s position in the obesity treatment market and provide new therapeutic options for patients struggling with current medications.
The most recent analyst rating on (AARD) stock is a Buy with a $33.00 price target. To see the full list of analyst forecasts on Aardvark Therapeutics, Inc. stock, see the AARD Stock Forecast page.
Spark’s Take on AARD Stock
According to Spark, TipRanks’ AI Analyst, AARD is a Underperform.
Aardvark Therapeutics, Inc. faces severe financial challenges typical of early-stage pharmaceutical companies, with zero revenue and substantial operational losses. The lack of technical and valuation indicators further contributes to the high-risk profile.
To see Spark’s full report on AARD stock, click here.
More about Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapies targeting metabolic disorders such as obesity and diabetes. The company is engaged in creating innovative treatments that modulate gut-brain axis signaling to control hunger and appetite.
Average Trading Volume: 163,788
Technical Sentiment Signal: Strong Sell
Current Market Cap: $225.4M
See more insights into AARD stock on TipRanks’ Stock Analysis page.